«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:

期数:

2024年06期

页码:

936-941

栏目:

论著

出版日期:

2024-12-25

文章信息/Info

Title:

Prognostic significance of SCARA5 methylation in adjuvant chemotherapy for resectable non-small cell lung cancer

作者:

焦 咪¹; 郭亚焕¹; 锻 炼¹; 方 芳²

710061 西安,陕西省肿瘤医院肿瘤内六科¹
710061 西安,西安市胸科医院呼吸与危重症医学科²

Author(s):

Jiao Mi¹;  Guo Yahuan¹;  Duan Lian¹;  Fang Fang².

¹Department of Oncology, Shaanxi Provincial Tumor Hospital, Xi'an 710061, China; ²Resipratory and Critical Care Medicine, Xi'an Chest Hospital, Xi'an 710061, China

关键词:

非小细胞肺癌;  A类清道夫受体5型;  辅助化疗;  预后

Keywords:

Non-small cell lung cancer;  Class A scavenger receptor type 5;  Adjuvant chemotherapy;  Prognosis

分类号:

R734.2

DOI:

10.3877/cma.j.issn.1674-6902.2024.06.015

摘要:

目的 分析A类清道夫受体5型(scavenger receptor class A member 5, SCARA5)甲基化对可切除非小细胞肺癌(non-small cell lung cancer, NSCLC)辅助化疗(adjuvant chemotherapy, ACT)的预后意义。 方法 选择2018年5月至2023年1月我院收治的69例ⅠA～ⅢA期NSCLC患者为对象,亚硫酸氢盐靶向测序和实时定量甲基化特异性聚合酶链式反应(real-time quantitative methylation-specific polymerase chain reaction, RQ-MSP)检测SCARA5甲基化水平; 实时荧光定量聚合酶链式反应(real-time fluorescence quantitative polymerase chain reaction, qRT-PCR)检测SCARA5 mRNA水平,采用Spearman分析两者相关性,Kaplan-Meier生存曲线和COX风险比例模型分析SCARA5甲基化水平对预后影响。 结果 NSCLC肿瘤组织SCARA5甲基化水平9.32(7.59,10.80)高于癌旁组织SCARA5甲基化水平7.45(6.36,8.55); 肿瘤组织SCARA5 mRNA,3.22(2.86,4.14)低于癌旁组织SCARA5 mRNA,4.01(3.53,4.46)(P<0.05)。SCARA5高甲基化者(中位值≥9.32)6个月、9个月、12个月ACT相对剂量强度(relative dose intensity, RDI)≥70%占比20(57.14%)、16(45.71%)、13(19.12%)低于SCARA5低甲基化者28(82.35%)、28(82.35%)、24(35.29%)(P<0.05)。复发30例(43.48%),中位无复发生存期21.00个月; 中位随访28.00个月,死亡28例(40.58%)。COD分析显示,SCARA5甲基化与NSCLC术后ACT的OS[HR:3.503(95%CI:1.327～9.248)]和DFS[HR:2.393(95%CI:1.075～5.329)]相关。肿瘤组织中SCARA5甲基化水平与SCARA5mRNA水平呈负相关(Rho=-0.254,P=0.035)。SCARA5高甲基化DFS 40.00%低于SCARA5低甲基化DFS 73.53%,SCARA5高甲基化OS 37.14%低于SCARA5低甲基化OS 82.35%(P<0.05)。 结论 可切除NSCLC经ACT后SCARA5高甲基化预后差,SCARA5可为NSCLC预后参考。

Abstract:

Objective To analyze prognostic significance of scavenger receptor class A member 5(SCARA5)methylation in adjuvant chemotherapy(ACT)for non-small cell lung cancer(NSCLC). Methods All of 69 patients with stage ⅠA～ⅢA NSCLC admitted to our hospital from May 2018 to January 2023 were selected as subjects. The methylation level of SCARA5 was detected by targeted bisulfite sequencing and real-time quantitative methylation-specific polymerase chain reaction(RQ-MSP). Real-time fluorescence quantitative polymerase chain reaction(qRT-PCR)was used to detect SCARA5 mRNA levels and Spearman was used to analyze the correlation. Kaplan-Meier survival curve and COX risk proportional model were used to analyze the effect of SCARA5 methylation on prognosis. Results The methylation level of SCARA5 in NSCLC tumor tissue was 9.32(7.59, 10.80)and 7.45(6.36, 8.55), respectively. SCARA5 mRNA in tumor tissue 3.22(2.86, 4.14)was lower than that in paracancer tissue4.01(3.53, 4.46)(P<0.05). SCARA5 hypermethylation(median ≥9.32)at 6 months, 9 months, 12 months relative dose intensity(relative dose intensity, RDI≥70% in 20(57.14%), 16(45.71%), 13(19.12%)were lower than those in SCARA5 hypomethyl group 28(82.35%), 28(82.35%), 24(35.29%)(P<0.05). There were 30 cases(43.48%)with recurrence, and the median relapse-free survival was 21.00months. The follow-up was 28.00months, and 28 cases(40.58%)died. COD analysis showed that SCARA5 methylation was correlated with OS[HR: 3.503(95%CI: 1.327-9.248)] and DFS[HR: 2.393(95%CI: 1.075-5.329)] of ACT after NSCLC. The methylation level of SCARA5 in tumor tissue was negatively correlated with the mrna level of ScarA5(Rho=-0.254, P=0.035). SCARA5 hypermethylated DFS 40.00% was lower than SCARA5 hypomethylated DFS 73.53%, and SCARA5 hypermethylated OS 37.14% was lower than SCARA5 hypomethylated OS 82.35%(P<0.05). Conclusion Hypermethylation of SCARA5 in resectable NSCLC after ACT has a poor prognosis, and SCARA5 can be a prognostic indicator of NSCLC.

参考文献/References:

1 韦 森. 可切除非小细胞肺癌新辅助免疫治疗应用现状及进展[J]. 癌症, 2020, 39(3): 95-103.
2 王 园, 杨 懿, 牟云飞, 等. 可切除非小细胞肺癌患者术后奥西替尼靶向治疗分析[J/CD]. 中华肺部疾病杂志(电子版), 2022, 15(5): 657-660.
3 Chaft JE, Shyr Y, Sepesi B, et al. Preoperative and postoperative systemic therapy for operable non-small-cell lung cancer[J]. J Clin Oncol, 2022, 40(6): 546-555.
4 Ou W, Li N, Wang BX, et al. Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC(GASTO1003, CORIN): a randomised, open-label, phase 2 trial[J]. EClinicalMedicine, 2023, 57: 101839.
5 Freitas AJA, Causin RL, Varuzza MB, et al. Molecular biomarkers predict pathological complete response of neoadjuvant chemotherapy in breast cancer patients[J]. Cancers, 2021, 13(21): 5477-5493.
6 Constâncio V, Nunes SP, Henrique R, et al. DNA methylation-based testing in liquid biopsies as detection and prognostic biomarkers for the four major cancer types[J]. Cells, 2020, 9(3): 624.
7 Müller D, Györffy B. DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer[J]. Biochim Biophys Acta Rev Cancer, 2022, 1877(3): 188722.
8 Dhar GA, Saha S, Mitra P, et al. DNA methylation and regulation of gene expression: Guardian of our health[J]. Nucleus, 2021, 64(3): 259-270.
9 Kiselev IS, Kulakova OG, Boyko AN, et al. DNA methylation as an epigenetic mechanism in the development of multiple sclerosis[J]. Acta Naturae, 2021, 13(2): 45.
10 Jiang X, Jiang Y, An D, et al. Methylated tumor suppressor gene SCARA5 inhibits the proliferation, migration and invasion of nasopharyngeal carcinoma[J]. Epigenomics, 2023, 15(11): 635-650.
11 Flockerzi FA, Hohneck J, Saar M, et al. SCARA5 is overexpressed in prostate cancer and linked to poor prognosis[J]. Diagnostics, 2023, 13(13): 2211.
12 Wieder R. Fibroblasts as turned agents in cancer progression[J]. Cancers, 2023, 15(7): 2014.
13 刘宝刚, 李磊强, 孙立哲, 等. 生物免疫疗法联合放化疗对NSCLC患者CD3⁺、CD4⁺/CD8⁺、NK的影响[J/CD]. 中华肺部疾病杂志(电子版), 2023, 16(5): 661-663.
14 陈 旭, 牛 凯, 孙建国. 放疗联合免疫治疗对驱动基因阴性NSCLC的困惑分析及应对策略[J/CD]. 中华肺部疾病杂志(电子版), 2024, 17(3): 341-348.
15 李梦琦, 杨 丽. 青年肺癌的诊断、分子遗传学特点及治疗研究进展[J]. 山东医药, 2023, 63(23): 89-92.
16 Liu J, Huang B, Ding F, et al. Environment factors, DNA methylation, and cancer[J]. Environmental Geochemistry and Health, 2023, 45(11): 7543-7568.
17 Ramazi S, Dadzadi M, Sahafnejad Z, et al. Epigenetic regulation in lung cancer[J]. MedComm, 2023, 4(6): e401.
18 Mattei AL, Bailly N, Meissner A. DNA methylation: a historical perspective. Trends Genet[J]. 2022, 38(7): 676-707.
19 Goldmann T, Schmitt B, Müller J, et al. DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer[J]. Clin Epigenetics, 2021, 13(1): 38.
20 Li Y, Fan Z, Meng Y, et al. Blood-based DNA methylation signatures in cancer: A systematic review[J]. Biochim Biophys Acta Mol Basis Dis, 2023, 1869(1): 166583.
21 薛剑超, 王亚东, 李博文, 等. DNA甲基化在肺癌发生及预后中作用的研究进展[J]. 基础医学与临床, 2023, 43(3): 514-518.
22 Zhang H, Liu C, Wang X, et al. SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression[J]. J Cancer, 2021, 12(8): 2412.
23 Zhang H, Liu C, Wang X, et al. SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression[J]. J Cancer, 2021, 12(8): 2412-2421.
24 Liu Y, Xiong R, Xiao T, et al. SCARA5 induced ferroptosis to effect ESCC proliferation and metastasis by combining with Ferritin light chain[J]. BMC Cancer, 2022, 22(1): 1304.
25 Huang J, Lv C, Zhao B, et al. SCARA5 inhibits oral squamous cell carcinoma via inactivating the STAT3 and PI3K/AKT signaling pathways[J]. Open Med(Wars), 2023, 18(1): 20230627.
26 Ni Q, Li X, Huang H, et al. Decreased expression of SCARA5 predicts a poor prognosis in melanoma using bioinformatics analysis[J]. Front Oncol, 2023, 13: 1015358.
27 Zhang C, Zhang J, Guo K. Paeonol upregulates expression of tumor suppressors TNNC1 and SCARA5, exerting anti-tumor activity in non-small cell lung cancer cells[J]. Naunyn Schmiedebergs Arch Pharmacol, Published online January 24, 2024.
28 Peng Q, Liu Y, Kong X, et al. The novel methylation biomarker SCARA5 sensitizes cancer cells to DNA damage chemotherapy drugs in NSCLC[J]. Front Oncol, 2021, 11: 666589.
29 Chaft JE, Rimner A, Weder W, et al. Evolution of systemic therapy for stages Ⅰ-Ⅲ non-metastatic non-small-cell lung cancer[J]. Nat Rev Clin Oncol, 2021, 18(9): 547-557.
30 Okumura N, Soh J, Suzuki H, et al. Randomized phase Ⅱ study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301[J]. BMC Cancer, 2021, 21(1): 506.
31 amamoto H, Soh J, Okumura N, et al. Randomized phase Ⅱ study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage Ⅳ(tumor diameter >2 cm)-ⅢA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201[J]. PLoS One, 2023, 18(5): e0285273.
32 Kayashima H, Itoh S, Shimokawa M, et al. Effect of duration of adjuvant chemotherapy with S-1(6 versus 12 months)for resected pancreatic cancer: the multicenter clinical randomized phase Ⅱ postoperative adjuvant chemotherapy S-1(PACS-1)trial[J]. Int J Clin Oncol, 2023, 28(11): 1520-1529.

备注/Memo

备注/Memo:

基金项目: 陕西省自然科学基础研究计划(2020JQ-951)
通信作者: 方 芳, Email: f15353724195@163.com

常用功能

更新日期/Last Update: 2024-12-25